文献速递免疫规划卫生政策与健康促进

孟加拉国、加纳和马拉维轮状病毒疫苗接种的成本与成本效果再评估:三种轮状病毒疫苗的比较

Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
PubMed 文献 · Vaccine · 2018-10-25

该建模研究再评估孟加拉国、加纳和马拉维轮状病毒疫苗接种的成本与成本效果,并比较Rotarix®、ROTAVAC®和ROTASIIL®。结果显示,与不接种相比,每避免一个DALY的贴现成本为各国人均GNI的0.3至1.3倍;在有Gavi补贴时,平均成本效果比均低于人均GNI的0.3倍。Rotarix®在受检国家中成本最低且最具成本效果,但其他产品若增量卫生系统成本小幅下降,可能达到或超过Rotarix®的成本与成本效果结果。

要点

  • 有Gavi补贴时,三种疫苗平均成本效果比均低于人均GNI的0.3倍。
  • 无补贴时,每避免一个DALY成本为各国人均GNI的0.3至1.3倍。
  • Rotarix®在受检国家中成本最低且最具成本效果。

核心结论

  • 国家可考虑进入市场的新轮状病毒疫苗,并仔细审查价格和增量卫生系统成本等产品属性。

研究设计与样本

  • 基于Excel的队列模型,使用与既往分析相同的数据,在孟加拉国、加纳和马拉维比较Rotarix®、ROTAVAC®和ROTASIIL®。
  • 改变每种疫苗的预期价格(有和无Gavi补贴)、浪费和增量卫生系统成本,并假设两剂或三剂接种后效力与衰减假设相同。

主要发现

  • 与不接种相比,每种疫苗每避免一个DALY的贴现成本为各国人均GNI的0.3至1.3倍。
  • 有Gavi补贴时,所有三国平均成本效果比均低于人均GNI的0.3倍。
  • Rotarix®在受检国家中成本最低且最具成本效果。
  • 其他产品增量卫生系统成本小幅下降可能使成本和成本效果结果达到或超过Rotarix®。

关键数值与推荐

  • 成本效果以每避免一个DALY的贴现成本相对于人均GNI的倍数表示。
  • 有Gavi补贴时平均成本效果比低于人均GNI的0.3倍。

临床怎么用

  • 国家选择轮状病毒疫苗时应综合评估价格和增量卫生系统成本,这些成本因国家而异。

局限性

  • 关键实证成本数据尚不可得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diarrhea is a leading cause of mortality worldwide and rotavirus accounts for many of these deaths. As of August 2018, 96 countries have introduced rotavirus vaccines into their immunization programs. Two rotavirus vaccines, Rotarix® and RotaTeq®, have been WHO-prequalified since 2009, with Rotarix® being the preferred product of most Gavi-supported countries. ROTAVAC® and ROTASIIL® have both been prequalified recently. MATERIALS AND METHODS: We reevaluated the costs and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi and compared Rotarix®, ROTAVAC®, and ROTASIIL® in each country. For consistency with previously published analyses in these countries, we used the same Excel-based cohort model and much of the same data as the original analyses. We varied the expected price (with and without Gavi subsidy), wastage, and incremental health system costs associated with each vaccine. We assumed the same efficacy and waning assumptions following administration of two or three doses for the respective product. RESULTS: The discounted cost per DALY averted compared to no vaccination ranged from 0.3 to 1.3 times GNI per capita for each vaccine. With the Gavi subsidy, the average cost-effectiveness ratios were below 0.3 times GNI per capita in all three countries. Though critical empirical cost data are not yet available, Rotarix® is the least costly and most cost-effective product in the countries examined in this modelling study. However, small decreases in the incremental health system cost for other products could result in cost and cost-effectiveness outcomes that match or surpass those of Rotarix®. CONCLUSION: Countries may wish to consider new rotavirus vaccines entering the market. Countries should carefully examine multiple product attributes including price and the incremental health system costs associated with each vaccine. These costs will vary by country and may be a defining factor in determining the least costly and most cost-effective product for the population.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pecenka C, Debellut F, Bar-Zeev N, et al. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines. Vaccine. 2018. PMID: 30420039. doi:10.1016/j.vaccine.2018.10.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。